Benzenesulfonamide, N-[2-(2-furanyl)phenyl]-3-(trifluoromethyl)- | 663595-93-5

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: Benzenesulfonamide, N-[2-(2-furanyl)phenyl]-3-(trifluoromethyl)-
• 英文别名: N-[2-(furan-2-yl)phenyl]-3-(trifluoromethyl)benzenesulfonamide
• CAS: 663595-93-5
• 化学式: C₁₇H₁₂F₃NO₃S
• 分子量: 367.3
• InChiKey: XFBMDTAAOHWXMX-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.1
• 重原子数：
  25
• 可旋转键数：
  4
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.06
• 拓扑面积：
  67.7
• 氢给体数：
  1
• 氢受体数：
  7

文献信息

• Sulfonamides as potassium channel blockers
  申请人：McNaughton-Smith A. Grant

  公开号：US20060094721A9

  公开（公告）日：2006-05-04

  Compounds, compositions and methods are provided which are useful in the treatment of diseases through the modulation of potassium ion flux through voltage-dependent potassium channels. More particularly, the invention provides sulfonamides, and compositions and methods utilizing sulfonamides that are useful in the treatment of diseases by blocking potassium channels associated with the onset or recurrence of the indicated conditions. Exemplary diseases treatable with the compounds, compositions and methods of the invention include sickle cell disease and glaucoma.

  本发明提供了在通过调节电压依赖性钾通道的钾离子通量来治疗疾病方面有用的化合物、组合物和方法。更具体地，本发明提供了磺酰胺、以及利用磺酰胺的组合物和方法，通过阻断与所述疾病的发生或复发有关的钾通道，用于治疗疾病。本发明的化合物、组合物和方法可用于治疗的示例疾病包括镰状细胞病和青光眼。
• TREATMENT AND DIAGNOSIS OF HEREDITARY XEROCYTOSIS
  申请人：Universite d'Aix Marseille

  公开号：EP3106155A1

  公开（公告）日：2016-12-21

  The invention relates to an in vitro method of diagnosis of hereditary xerocytosis in a subject, comprising genotyping the KCNN4 gene encoding the Gardos channel in said subject. The invention also relates to an inhibitor of the KCNN4 protein for use in the treatment of hereditary xerocytosis, in particular in a human subject who is a carrier of the missense mutation c.1055G>A in the KCNN4 gene.

  本发明涉及一种体外诊断遗传性粒细胞增多症的方法，包括对所述受试者中编码加多斯通道的 KCNN4 基因进行基因分型。本发明还涉及一种 KCNN4 蛋白抑制剂，用于治疗遗传性粒细胞增多症，特别是用于治疗 KCNN4 基因中 c.1055G>A 缺失突变的携带者。
• SULFONAMIDES AS POTASSIUM CHANNEL BLOCKERS
  申请人：Icagen, Inc.

  公开号：EP1534259A2

  公开（公告）日：2005-06-01
• EP1534259A4
  申请人：——

  公开号：EP1534259A4

  公开（公告）日：2006-10-04
• Treatment and Diagnosis of Hereditary Xerocytosis
  申请人：Universite d'aix Marseille

  公开号：US20180136227A1

  公开（公告）日：2018-05-17

  The invention relates to an in vitro method of diagnosis of hereditary xerocytosis in a subject, comprising genotyping the KCNN4 gene encoding the Gardos channel in said subject. The invention also relates to an inhibitor of the KCNN4 protein for use in the treatment of hereditary xerocytosis, in particular in a human subject who is a carrier of the missense mutation c.1055G>A or c.844G>A in the KCNN4 gene.